Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06448754
Other study ID # D798KC00001
Secondary ID 2023-509482-20
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 28, 2024
Est. completion date January 3, 2028

Study information

Verified date May 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.


Description:

This is a platform, randomized, open-label, multicenter, global study. Enrolled participants with Stage IV non-squamous non-small cell lung cancer (NSQ NSCLC) who are treatment-naïve and have not received previous treatment for advanced or metastatic disease. These participants will be randomized in a 1:1 ratio to one of the two treatment arms: Arm 1A and Arm 1B. Both arms will test a volrustomig dosing in combination with chemotherapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date January 3, 2028
Est. primary completion date August 26, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 130 Years
Eligibility Key Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration. - Life expectancy greater than or equal to (>=) 12 weeks. - Adequate organ and bone marrow function. - Body weight greater than (>) 35 kilograms (kg) at screening and at randomization. - Histologically or cytologically documented NSQ NSCLC. - Absence of sensitizing epidermal growth factor receptor (EGFR) mutations. - Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies. - At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter. Key Exclusion Criteria: - Spinal cord compression. - History of primary active immunodeficiency. - Active or prior documented autoimmune or inflammatory disorders. - Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. - Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment. - Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.

Study Design


Intervention

Drug:
Volrustomig
Participants will receive volrustomig via intravenous (IV) infusion.
Carboplatin
Participants will receive carboplatin via IV infusion.
Pemetrexed
Participants will receive pemetrexed via IV infusion.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. From screening (Days -28 to Day -1) up to 2.4 years
Primary Objective Response rate (ORR) ORR is defined as the percentage of participants who have a complete response (CR) or partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). Up to 2.4 years
Secondary Disease Control Rate (DCR) DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. Up to 2.4 years
Secondary Duration of Response (DOR) DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). Up to 2.4 years
Secondary Progression Free Survival (PFS) PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). Up to 2.4 years
Secondary Overall Survival (OS) OS is defined as the time from randomization or first dose until the date of death due to any cause. Up to 2.4 years
Secondary Serum Concentration of Volrustomig The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. Up to 2.4 years
Secondary Trough concentration (Ctrough) The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. Up to 2.4 years
Secondary Maximum Observed Concentration (Cmax) The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. Up to 2.4 years
Secondary Area Under the Curve (AUC) The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. Up to 2.4 years
Secondary Number of Participants with Positive Antidrug Antibodies (ADAs) The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. Up to 2.4 years
See also
  Status Clinical Trial Phase
Terminated NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT05042375 - A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Phase 3
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Recruiting NCT05009836 - Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Recruiting NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT04054531 - Study of KN046 With Chemotherapy in First Line Advanced NSCLC Phase 2
Withdrawn NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Terminated NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01871805 - A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT05919641 - LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Completed NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma Phase 1